+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Onychomycosis R&D Pipeline Analysis Report, H2-2018

  • ID: 4614303
  • Report
  • 50 pages
  • VPA Research
1 of 4
Comprehensive Pipeline Review on Ongoing Clinical and Pre-Clinical Studies

FEATURED COMPANIES

  • Acea Biotech Inc
  • Almirall SA
  • Global Health Solutions
  • Hexima Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • MORE
Onychomycosis Drug Development Pipeline Study is the latest publication from this researcher with comprehensive information of Onychomycosis pipeline products.

The Onychomycosis pipeline guide presents complete overview of drugs currently being developed for Onychomycosis. The pipeline review provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials).

Drug development phase, current stage, mechanism of action, route of administration, orphan drug/ fast track/ other designations, drug class are provided for each of the Onychomycosis pipeline candidate.
Research and Development progress along with latest news related to each of the Onychomycosis pipeline candidates is included.

Major companies participating in therapeutic development of Onychomycosis are included in this pipeline report. Company wise pre clinical and clinical products along with details of drug originator, co developers/ licensors are provided.

Amid strong interest for cure of Onychomycosis from companies and institutes, the current research work serves as a reliable and comprehensive source of information of global Onychomycosis clinical and pre clinical products.

The report assists in identifying potential upcoming companies and drugs in Onychomycosis pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

Information in the report is sourced from our proprietary platform, built through extensive primary and secondary research methodology. Data is presented in user friendly and ready to use format.

Scope of Onychomycosis pipeline report includes
  • Panorama of Onychomycosis pipeline markets including statistics on therapeutic drugs and companies involved
  • Onychomycosis Pipeline candidates across various development phases including both pre clinical, discovery and clinical stages are covered
  • Onychomycosis pipeline candidates across various ‘Mechanism of Actions’ are also presented in the study
  • Overview of companies participating in Onychomycosis pipeline with short introduction to their businesses and pipeline projects
  • For each pipeline candidate, drug overview, details of mechanism of Action (MOA), originator, co developer and licensee are provided.
  • Research and Development progress and trial details, results wherever available, are also included in the pipeline study
  • The pipeline study provides information on all ongoing and active projects and also presents the recent news associated with Onychomycosis pipeline therapeutics
Reasons to Buy
  • Get clear understanding of the entire Onychomycosis pipeline, with details on active projects
  • Get in detail information of each product with updated information on each project along with key milestones
  • Know the list of companies participating in global Onychomycosis pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
  • Get trial information for each pipeline product under development
  • Understand the pipeline structure in terms of mechanism of Action, phase and company
Please Note: The report will be delivered in 2 working days after purchase
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acea Biotech Inc
  • Almirall SA
  • Global Health Solutions
  • Hexima Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • MORE
I. Key Findings

1. Companies Investing in Onychomycosis Pipeline include
Number of Companies with Onychomycosis projects in pre clinical Development
Number of Companies with Onychomycosis projects in Clinical Development
Onychomycosis Pipeline Companies based in Americas
Onychomycosis Pipeline Companies based in Europe
Onychomycosis Pipeline Companies based in Asia Pacific
Onychomycosis Pipeline Companies based in Rest of the World

2. Pipeline Candidates include
Onychomycosis Pipeline Agents in pre clinical/ Discovery stage of Development
Onychomycosis Pipeline Agents in Clinical Development stage
Onychomycosis Pipeline Therapeutic Compounds received special status
Mechanism of Action of most pipeline Drugs
Small molecules among the Onychomycosis Pipeline agents

II. Insights into Onychomycosis Pipeline -

1. Disease Overview
Introduction to Onychomycosis
Symptoms and Causes of Onychomycosis
Treatment or Prevention Options for Onychomycosis
Other Details
2. Phase wise Pipeline Compounds
Onychomycosis Pipeline Pre Clinical/ Discovery stage Drugs
Onychomycosis Pipeline Phase 1 stage Drugs
Onychomycosis Pipeline Phase 2 stage Drugs
Onychomycosis Pipeline Phase 3 stage Drugs
Onychomycosis Pipeline Pre Registration stage Drugs
3. Company wise Onychomycosis Pipeline Compounds
4. Onychomycosis Pipeline by Mechanism of Action

III. Onychomycosis Pipeline Compound Details

Drug Details

1. Snapshot
Name of the Therapeutic Agent
Originator
Developing Company
Co Developer/ License Partner
Orphan Drug / Fast Track/ Designation
Development Phase
2. Drug Overview
3. Mechanism of Action
4. Current Status
5. Clinical Trial Details

IV. Onychomycosis Pipeline Company Briefs

V. Latest News and Developments in Global Onychomycosis Pipeline Market

VI. Appendix
1. About Us
2. Research Methodology
3. Contact Information

The report will be delivered within 2 working days after procurement. Some of the sections depicted above may be modified in accordance with relevancy and availability
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Acea Biotech Inc
  • Almirall SA
  • Blueberry Therapeutics Ltd
  • Exodos Life Sciences Limited Partnership
  • Global Health Solutions
  • Hexima Ltd
  • Kaken Pharmaceutical Co Ltd
  • Meiji Seika Pharma Co Ltd
  • Moberg Pharma AB
  • NAL Pharmaceuticals Ltd
  • Novabiotics Ltd
  • Novan Inc
  • Rich Point Pharma
  • Sanotize Research And Development Corp
  • Viamet Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4614303
Adroll
adroll